Welcome to our dedicated page for Dynatronics SEC filings (Ticker: DYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dynatronics Corporation (DYNT) SEC filings page provides access to the company’s regulatory disclosures as a reporting issuer under the Securities Exchange Act of 1934. These documents include annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy statements on Schedule 14A, current reports on Form 8-K, and other required submissions that describe the company’s business, governance, and financial condition over time.
For a medical device company like Dynatronics, periodic reports such as Form 10-K and Form 10-Q have historically contained information on its restorative products for physical therapy, rehabilitation, orthopedics, pain management, and athletic training, as well as discussions of its brand portfolio, distribution channels, and risk factors. Proxy statements, including the definitive proxy statement (DEF 14A) dated October 28, 2025, provide detail on board structure, executive compensation, and shareholder voting matters.
Current reports on Form 8-K are particularly significant for understanding key events affecting Dynatronics. An 8-K filed on December 17, 2025 reports the results of the company’s 2025 Annual Meeting of Shareholders, including director elections and advisory votes on executive compensation. Another 8-K, filed on January 12, 2026, discloses that on January 9, 2026 Dynatronics and its wholly-owned subsidiaries ceased operations and filed voluntary petitions for relief under Chapter 7 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Minnesota. That filing explains that a Chapter 7 trustee will be appointed to administer and liquidate the assets of each Debtor and that the authority of the Board of Directors and executive officers is effectively eliminated upon the trustee’s appointment.
Other filings, such as the Form 12b-25 notification of late filing submitted on November 17, 2025, document timing and process issues related to specific periodic reports, while affirming the company’s intent to file within the allowed extension period. Together, these filings trace Dynatronics’ evolution from an operating medical device company trading on Nasdaq and then OTCQB to an entity in Chapter 7 liquidation.
On this page, users can review Dynatronics’ historical SEC filings, including Forms 10-K, 10-Q, 8-K, DEF 14A, and any available Form 4 insider transaction reports, alongside AI-powered summaries that explain the key points, highlight material events, and help interpret the implications of the company’s Chapter 7 bankruptcy and liquidation process.
Form 4 filed on 07/02/2025 shows that Provco Ventures 1 LP, a 10% beneficial owner of Dynatronics Corp. (DYNT), received 522,122 shares of common stock on 07/01/2025. The transaction is coded “J,” indicating a non-open-market acquisition tied to a contractual arrangement. The footnote clarifies that the shares represent payment of the 8% preferred-stock quarterly dividend, valued at $0.0655 per share (90% of the 10-day average closing bid price). After the issuance, Provco’s direct holdings rose to 2,155,561 shares, implying a step-up of roughly 32% from the prior 1,633,439 share position. Because the dividend was paid in equity rather than cash, the transaction increases the public float and introduces incremental dilution for existing common shareholders, although the exact percentage of dilution cannot be calculated from the filing alone.
No derivative securities were reported in Table II, and there were no sales or option exercises disclosed. The filing is made by a single reporting person and does not amend a prior Form 4.